X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-11-20 | ANNX | Annexon, Inc. | Satter Muneer A | Dir | P - Purchase | $4.38 | +822,613 | 9,728,637 | +9% | +$3,600,784 | |||||
| D | 2025-11-20 | PRAX | Praxis Precision Medicines, Inc. | Nemiroff Alex | GC, Secretary | S - Sale+OE | $193.09 | -25,130 | 20,832 | -55% | -$4,852,256 | |||||
| D | 2025-11-20 | PRAX | Praxis Precision Medicines, Inc. | Mastrocola Lauren | Principal Accounting Officer | S - Sale+OE | $192.08 | -13,600 | 10,442 | -57% | -$2,612,244 | |||||
2025-11-19 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $20.23 | -1,300,000 | 18,047,727 | -7% | -$26,304,500 | ||||||
2025-11-19 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $20.23 | -1,300,000 | 18,047,727 | -7% | -$26,304,500 | ||||||
2025-11-19 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $20.23 | -1,300,000 | 18,047,727 | -7% | -$26,304,500 | ||||||
2025-11-21 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $3.50 | +20,000 | 2,713,896 | +1% | +$69,900 | ||||||
| M | 2025-11-19 | PGEN | Precigen, Inc. | Kirk Randal J | Dir, 10% | S - Sale | $4.14 | -2,966,293 | 123,946,220 | -2% | -$12,291,748 | |||||
| M | 2025-11-20 | SILO | Silo Pharma, Inc. | Weisblum Eric | CEO | P - Purchase | $0.37 | +2,000 | 211,932 | +1% | +$735 | |||||
2025-11-19 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $28.29 | -2,550 | 151,476 | -2% | -$72,135 | ||||||
| D | 2025-11-20 | ARQT | Arcutis Biotherapeutics, Inc. | Gilbert Halley E | Dir | S - Sale+OE | $27.55 | -16,532 | 22,123 | -43% | -$455,442 | |||||
2025-11-20 | SGMT | Sagimet Biosciences Inc. | Kemble George | Exec COB | S - Sale | $7.69 | -37,688 | 81,005 | -32% | -$289,979 | ||||||
2025-11-20 | MLYS | Mineralys Therapeutics, Inc. | Slingsby Brian Taylor | Dir, 10% | S - Sale | $43.35 | -1,000,000 | 7,903,838 | -11% | -$43,350,000 | ||||||
| M | 2025-11-20 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | See Remarks | P - Purchase | $2.89 | +2,450 | 10,000 | +32% | +$7,075 | |||||
2025-11-21 | MDGL | Madrigal Pharmaceuticals, Inc. | Huntsman Carole | Chief Commercial Officer | S - Sale | $553.11 | -1,958 | 10,032 | -16% | -$1,082,986 | ||||||
2025-11-19 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $22.33 | -12,500 | 902,688 | -1% | -$279,155 | ||||||
| DM | 2025-11-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $476.51 | -8,000 | 644,489 | -1% | -$3,812,082 | |||||
2025-11-21 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.33 | +580,000 | 250,402,576 | 0% | +$768,807 | ||||||
2025-11-19 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | S - Sale | $6.42 | -12,607 | 84,821 | -13% | -$80,934 | ||||||
2025-11-19 | RPRX | Royalty Pharma Plc | Lloyd George W. | EVP, Investments, CLO | S - Sale | $38.34 | -135,426 | 999,915 | -12% | -$5,192,656 | ||||||
| D | 2025-11-19 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $86.23 | -4,302 | 0 | -100% | -$370,965 | |||||
2025-11-19 | FULC | Fulcrum Therapeutics, Inc. | Gould Robert J | Dir | S - Sale | $11.03 | -15,000 | 484,864 | -3% | -$165,495 | ||||||
2025-11-20 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $35.83 | +5,784 | 373,151 | +2% | +$207,244 | ||||||
| D | 2025-11-19 | NUVB | Nuvation Bio Inc. | Hanley David C. | CHIEF TECHNICAL OPERATIONS | S - Sale+OE | $7.14 | -200,000 | 24,000 | -89% | -$1,427,680 | |||||
| E | 2025-11-20 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.17 | -37,148 | 92,607,304 | 0% | -$6,318 | |||||
2025-11-19 | SLS | Sellas Life Sciences Group, Inc. | Kalin Katherine Bach | Dir | P - Purchase | $1.59 | +63,400 | 104,400 | +155% | +$100,806 | ||||||
2025-11-18 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $181.09 | -18,000 | 393,332 | -4% | -$3,259,538 | ||||||
| DM | 2025-11-18 | TENX | Tenax Therapeutics, Inc. | Giordano Christopher Thomas | CEO | P - Purchase | $7.68 | +2,605 | 2,605 | New | +$20,000 | |||||
| AM | 2025-11-17 | TENX | Tenax Therapeutics, Inc. | Almenoff June Sherie | Dir | P - Purchase | $7.50 | +1,993 | 1,993 | New | +$14,945 | |||||
| D | 2025-11-18 | JAZZ | Jazz Pharmaceuticals Plc | Carr Patricia | SVP, Chief Accounting Officer | S - Sale+OE | $182.07 | -5,319 | 7,012 | -43% | -$968,402 | |||||
2025-11-20 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.33 | +580,000 | 249,822,576 | 0% | +$771,328 | ||||||
2025-11-18 | JAZZ | Jazz Pharmaceuticals Plc | Winningham Rick E | Dir | S - Sale | $180.86 | -5,500 | 8,893 | -38% | -$994,728 | ||||||
| M | 2025-11-18 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.92 | -102,753 | 3,413,127 | -3% | -$94,930 | |||||
| M | 2025-11-18 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $0.92 | -160,103 | 5,321,436 | -3% | -$147,913 | |||||
| M | 2025-11-18 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $0.92 | -160,103 | 5,321,436 | -3% | -$147,913 | |||||
2025-11-19 | SAVA | Cassava Sciences Inc | Barry Richard | Pres, CEO | P - Purchase | $2.75 | +73,385 | 788,060 | +10% | +$201,809 | ||||||
| D | 2025-11-19 | IONS | Ionis Pharmaceuticals Inc | Herman Joan E | Dir | S - Sale+OE | $72.13 | -44,000 | 46,086 | -49% | -$3,173,830 | |||||
2025-11-20 | SLRX | Salarius Pharmaceuticals, Inc. | Rosenblum Mark J | EVP Finance, CFO | P - Purchase | $0.80 | +20,000 | 20,177 | >999% | +$16,000 | ||||||
| DM | 2025-11-18 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $473.67 | -8,000 | 644,489 | -1% | -$3,789,373 | |||||
| D | 2025-11-18 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $30.03 | -35,656 | 174,998 | -17% | -$1,070,710 | |||||
2025-11-18 | RCKT | Rocket Pharmaceuticals, Inc. | Schwartz Jonathan David | See Remarks | S - Sale | $2.98 | -2,545 | 299,064 | -1% | -$7,592 | ||||||
2025-11-18 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $2.98 | -6,276 | 1,184,534 | -1% | -$18,721 | ||||||
2025-11-18 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $2.98 | -1,086 | 65,920 | -2% | -$3,240 | ||||||
2025-11-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $2.98 | -1,646 | 383,816 | 0% | -$4,910 | ||||||
| M | 2025-11-18 | SILO | Silo Pharma, Inc. | Weisblum Eric | CEO | P - Purchase | $0.40 | +12,000 | 209,932 | +6% | +$4,847 | |||||
| E | 2025-11-19 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.04 | -167,526 | 92,644,452 | 0% | -$6,317 | |||||
2025-11-19 | LITS | Lite Strategy, Inc. | Flynn James P | Dir | P - Purchase | $1.88 | +12,100 | 30,000 | +68% | +$22,777 | ||||||
2025-11-19 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $25.00 | -10,000 | 139,025 | -7% | -$250,000 | ||||||
2025-11-18 | ITRM | Iterum Therapeutics Plc | Dunne Michael W. | Dir | P - Purchase | $0.37 | +6,000 | 241,001 | +3% | +$2,191 | ||||||
| M | 2025-11-17 | ANNX | Annexon, Inc. | Satter Muneer A | Dir | P - Purchase | $3.37 | +1,500,000 | 8,906,024 | +20% | +$5,055,000 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% | P - Purchase | $6.09 | +507,874 | 15,705,828 | +3% | +$3,094,725 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% | P - Purchase | $6.09 | +507,874 | 15,705,828 | +3% | +$3,094,725 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Tananbaum James B. | Dir, 10% | P - Purchase | $6.09 | +507,874 | 15,705,828 | +3% | +$3,094,725 | |||||
| M | 2025-11-17 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $6.34 | +241,338 | 5,009,248 | +5% | +$1,529,865 | |||||
| M | 2025-11-17 | SION | Sionna Therapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $40.34 | -136,351 | 168,193 | -45% | -$5,500,158 | |||||
2025-11-17 | JAZZ | Jazz Pharmaceuticals Plc | Iannone Robert | EVP, Global Head of R, D, CMO | S - Sale | $168.26 | -7,159 | 72,628 | -9% | -$1,204,573 | ||||||
| M | 2025-11-18 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | COO | S - Sale | $16.17 | -125,589 | 170,981 | -42% | -$2,030,923 | |||||
2025-11-17 | TENX | Tenax Therapeutics, Inc. | McGauley Thomas | Interim CFO | P - Purchase | $7.27 | +8,000 | 8,000 | New | +$58,164 | ||||||
2025-11-19 | CYTK | Cytokinetics Inc | Parshall B Lynne | Dir | S - Sale | $64.73 | -5,000 | 22,933 | -18% | -$323,650 | ||||||
2025-11-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $21.82 | -12,500 | 890,392 | -1% | -$272,739 | ||||||
| DM | 2025-11-17 | TENX | Tenax Therapeutics, Inc. | Almenoff June Sherie | Dir | P - Purchase | $7.50 | +1,993 | 1,993 | New | +$14,945 | |||||
2025-11-12 | NATR | Natures Sunshine Products Inc | Norman Daniel C | EVP, Pres, Asia | S - Sale | $20.46 | -8,884 | 63,065 | -12% | -$181,767 | ||||||
| D | 2025-11-18 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $23.69 | -10,262 | 53,338 | -16% | -$243,114 | |||||
| D | 2025-11-18 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $23.69 | -4,084 | 25,058 | -14% | -$96,754 | |||||
2025-11-18 | NATR | Natures Sunshine Products Inc | Lanoy Jonathan David | SVP, Chief Accounting Officer | S - Sale | $20.45 | -5,000 | 46,233 | -10% | -$102,250 | ||||||
| D | 2025-11-17 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $75.99 | -2,812 | 103,901 | -3% | -$213,687 | |||||
| DM | 2025-11-17 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $99.62 | -20,729 | 61,734 | -25% | -$2,065,030 | |||||
| D | 2025-11-17 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $105.50 | -24,200 | 49,086 | -33% | -$2,552,999 | |||||
| M | 2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Lo Andrew | Dir | S - Sale | $66.11 | -95,599 | 64,672 | -60% | -$6,319,662 | |||||
| D | 2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Scott Randal W. | Dir | S - Sale+OE | $66.65 | -10,000 | 15,589 | -39% | -$666,465 | |||||
2025-11-19 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.31 | +580,000 | 249,242,576 | 0% | +$759,115 | ||||||
2025-11-17 | ONC | Beone Medicines Ltd. | Wu Xiaobin | Pres, COO | S - Sale | $380.43 | -3,991 | 985,343 | 0% | -$1,518,303 | ||||||
2025-11-17 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.30 | -69,594 | 829,306 | -8% | -$2,735,329 | ||||||
| DM | 2025-11-17 | NUVB | Nuvation Bio Inc. | Liu Dongfang | CHIEF MEDICAL OFFICER | S - Sale+OE | $4.93 | -30,000 | 18,000 | -63% | -$148,028 | |||||
| M | 2025-11-17 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $20.26 | -50,000 | 1,404,280 | -3% | -$1,012,764 | |||||
| D | 2025-11-17 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $41.24 | -12,470 | 22,714 | -35% | -$514,224 | |||||
2025-11-17 | PCRX | Pacira Biosciences, Inc. | Slonin Jonathan | Chief Medical Officer | S - Sale | $24.09 | -3,960 | 178,367 | -2% | -$95,396 | ||||||
2025-11-17 | AMRX | Amneal Pharmaceuticals, Inc. | Nark Ted C | Dir | S - Sale | $11.72 | -50,000 | 291,029 | -15% | -$586,000 | ||||||
| D | 2025-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $14.48 | -4,466 | 403,879 | -1% | -$64,665 | |||||
| D | 2025-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $14.48 | -2,683 | 133,574 | -2% | -$38,848 | |||||
| D | 2025-11-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $14.48 | -3,075 | 125,877 | -2% | -$44,524 | |||||
2025-11-17 | VRTX | Vertex Pharmaceuticals Inc / Ma | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Offi | S - Sale | $434.58 | -2,500 | 16,852 | -13% | -$1,086,450 | ||||||
2025-11-17 | CYPH | Cypherpunk Technologies Inc. | Mirabelli Christopher | Dir | S - Sale | $3.14 | -676,319 | 23,050 | -97% | -$2,123,642 | ||||||
2025-11-17 | CYPH | Cypherpunk Technologies Inc. | Cavanaugh James H | Dir | S - Sale | $3.14 | -261,840 | 213 | -100% | -$822,178 | ||||||
| D | 2025-11-17 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale+OE | $452.18 | -12,128 | 21,801 | -36% | -$5,483,990 | |||||
2025-11-17 | CYPH | Cypherpunk Technologies Inc. | Onsi Douglas E | CEO,CFO,Pres,GC,Treas., Sec. | S - Sale | $3.14 | -676,319 | 108,282 | -86% | -$2,123,642 | ||||||
2025-11-17 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $3.32 | -6,016 | 235,264 | -2% | -$19,973 | ||||||
| DM | 2025-11-17 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $6.07 | -22,463 | 834,592 | -3% | -$136,366 | |||||
2025-11-17 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $84.77 | -2,712 | 81,180 | -3% | -$229,896 | ||||||
| DM | 2025-11-17 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $6.15 | -77,920 | 7,614 | -91% | -$478,849 | |||||
| E | 2025-11-18 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $0.17 | -60,213 | 92,811,978 | 0% | -$10,350 | |||||
| D | 2025-11-18 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.75 | -6,500 | 0 | -100% | -$24,402 | |||||
2025-11-18 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | COB, Pres, CEO | P - Purchase | $1.27 | +5,000 | 276,421 | +2% | +$6,350 | ||||||
| M | 2025-11-17 | CRVO | Cervomed Inc. | Winton Matthew | Chief Commercial, Business | P - Purchase | $8.29 | +5,000 | 15,000 | +50% | +$41,430 | |||||
2025-11-17 | CRVO | Cervomed Inc. | Gregoire Sylvie | Dir, 10% | P - Purchase | $8.46 | +21,600 | 1,496,578 | +1% | +$182,736 | ||||||
| M | 2025-11-17 | CRVO | Cervomed Inc. | Elder William Robert | CFO, GC, Secretary | P - Purchase | $8.36 | +3,500 | 12,500 | +39% | +$29,250 | |||||
2025-11-17 | CRVO | Cervomed Inc. | Alam John J | CEO, Pres, 10% | P - Purchase | $8.46 | +21,600 | 1,496,578 | +1% | +$182,736 | ||||||
2025-11-14 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale | $11.42 | -30,000 | 48,473 | -38% | -$342,600 | ||||||
| DM | 2025-11-17 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $44.19 | -10,560 | 66,520 | -14% | -$466,631 | |||||
2025-11-17 | BBIO | Bridgebio Pharma, Inc. | Trimarchi Thomas | Pres, CFO | S - Sale | $66.46 | -16,934 | 382,830 | -4% | -$1,125,404 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |